Shingles Vaccine Side Effects and Recommendations
Vaccine Efficacy and Side Effects
- The recombinant zoster vaccine (Shingrix/RZV) has higher efficacy (91.3% against HZ in adults ≥70 years) and longer protection (>83.3% for up to 8 years) compared to the live zoster vaccine (ZVL, Zostavax) 1
- RZV is associated with significantly higher rates of injection-site reactions (up to 9.5% grade 3) and systemic symptoms (up to 11.4% grade 3) compared to placebo, though these side effects are generally mild to moderate and temporary 1
- The most common side effects of RZV include injection site reactions (pain, redness, and swelling) and systemic symptoms (fatigue, myalgia, headache, fever, and gastrointestinal symptoms) 1
- Despite higher reactogenicity, RZV has no significant difference in serious adverse events (SAEs) or deaths compared to placebo 1
- ZVL has lower efficacy compared to RZV (70% vs 96%) and is contraindicated in immunocompromised patients due to risk of vaccine-strain VZV infection 2, 3, 4
Special Considerations and Recommendations
- The CDC Advisory Committee on Immunization Practices recommends RZV for prevention of herpes zoster in immunocompetent adults aged ≥50 years 2, 3
- RZV is preferred over ZVL for prevention of herpes zoster and related complications, and is recommended for adults who previously received ZVL 2, 3
- RZV is suggested as the preferred vaccine for immunocompromised adults, including those with solid cancers 1
- Patients taking JAK inhibitors have increased risk of herpes zoster and should ideally be vaccinated before starting therapy 6
- The benefits of vaccination in preventing herpes zoster and its complications (particularly postherpetic neuralgia) outweigh the temporary side effects 1, 7